Loading…
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $53M | $-3M | $-7M | $-14M | -13.7% | -1.2% | -325.2% |
| 2024 | $53M | $7M | $3M | $7M | 6.8% | -18.5% | -64.7% |
| 2023 | $65M | $13M | $8M | $-2M | 24.8% | 37.5% | - |
| 2022 | $48M | $-11M | $-15M | $-26M | 140.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 47.64 | 65.49 | 53.40 | 52.74 |
| Cost Of Revenue | 19.59 | 22.98 | 24.32 | 26.99 |
| Gross Profit | 28.05 | 42.51 | 29.08 | 25.75 |
| Operating Expense | 41.06 | 32.05 | 25.16 | 31.25 |
| Operating Income | -13.01 | 10.46 | 3.92 | -5.50 |
| EBITDA | -10.78 | 12.94 | 6.52 | -2.95 |
| EBIT | -11.87 | 11.75 | 5.22 | -4.42 |
| Pretax Income | -14.40 | 8.57 | 4.15 | -5.61 |
| Tax Provision | 0.53 | 0.25 | 1.22 | 1 |
| Net Income | -14.93 | 8.31 | 2.93 | -6.60 |
| Net Income Common Stockholders | -14.93 | 8.31 | 2.93 | -6.60 |
| Total Expenses | 60.65 | 55.03 | 49.48 | 58.24 |
| Interest Expense | 2.53 | 3.18 | 1.06 | 1.19 |
| Interest Income | 1.15 | 1.29 | 1.30 | 1.08 |
| Research And Development | 29.35 | 17.09 | 12.97 | 19.57 |
| Selling General And Administration | 11.71 | 14.96 | 12.19 | 11.68 |
| Normalized EBITDA | -10.78 | 12.94 | 6.52 | -2.95 |
| Normalized Income | -14.93 | 8.31 | 2.93 | -6.60 |
| Basic EPS | -0.31 | 0.12 | 0.04 | -0.08 |
| Diluted EPS | -0.31 | 0.09 | 0.04 | -0.08 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.04 | 0.03 | 0.29 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -14.93 | 8.31 | 2.93 | -6.60 |
| Reconciled Depreciation | 1.09 | 1.19 | 1.30 | 1.47 |
| Reconciled Cost Of Revenue | 19.59 | 22.98 | 24.32 | 26.99 |
| Net Interest Income | -1.38 | -1.89 | 0.24 | -0.11 |
| Net Income From Continuing And Discontinued Operation | -14.93 | 8.31 | 2.93 | -6.60 |
| Total Operating Income As Reported | -13.01 | 10.46 | 3.92 | -5.50 |
| Diluted Average Shares | 48.47 | 82.42 | 81.06 | 78.55 |
| Basic Average Shares | 48.47 | 67.51 | 72.53 | 78.55 |
| Diluted NI Availto Com Stockholders | -14.93 | 8.31 | 2.93 | -6.60 |
| Net Income Including Noncontrolling Interests | -14.93 | 8.31 | 2.93 | -6.60 |
| Net Income Continuous Operations | -14.93 | 8.31 | 2.93 | -6.60 |
| Net Non Operating Interest Income Expense | -1.38 | -1.89 | 0.24 | -0.11 |
| Interest Expense Non Operating | 2.53 | 3.18 | 1.06 | 1.19 |
| Interest Income Non Operating | 1.15 | 1.29 | 1.30 | 1.08 |
| Operating Revenue | 47.64 | 65.49 | 53.40 | 52.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Protalix BioTherapeutics, Inc.this co. | PLX | $171M | - | 3.53 | -13.7% | -36.89 |
| CVRx, Inc. | CVRX | $181M | - | 4.60 | -135.6% | -3.08 |
| AirSculpt Technologies, Inc. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Stereotaxis, Inc. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $176M |
| - |
| 0.65 |
| -50.6% |
| 0.32 |
| Alpha Teknova, Inc. | TKNO | $173M | - | 2.52 | -25.1% | -17.76 |
| Sanara MedTech Inc. | SMTI | $167M | - | 27.41 | -633.5% | 16.81 |
| Journey Medical Corporation | DERM | $166M | - | 4.26 | -35.9% | -35.25 |
| Anika Therapeutics, Inc. | ANIK | $165M | - | 1.20 | -7.6% | -31.67 |
| Peer Median | - | - | 3.39 | -43.2% | -6.28 | |